Post-earnings recap
Reported
Mon, Feb 2, 2026
EPS actual
$-0.50
EPS est.
$-0.47
EPS surprise
-5.26%
1-day move
+13.98%
Despite missing on EPS, Twist Bioscience's stock rose by nearly 14% following the earnings report. This increase may be attributed to investor optimism about the company's future strategies and potential for recovery. The lack of revenue data and guidance leaves some uncertainty, but the positive stock reaction suggests confidence in management's direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.50 | N/A | -5.26% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution regarding current market conditions. They highlighted the need for strategic adjustments moving forward.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—